NIH Faces Anti-Allergy Vaccine Shortage, Losing Millions Daily
Dr. Zulfiqar Soomro, In-Charge of the NIH Anti-Allergy Center, said efforts are underway to stabilize the situation.
ISLAMABAD: The National Institute of Health (NIH) continues to face a shortage of the anti-allergy vaccine, causing daily losses of Rs 1.2 to 1.5 million, sources reported on Tuesday.
According to officials, 1,200 to 1,500 patients are sent home every day due to the unavailability of the vaccine. The ongoing shortage has resulted in losses worth billions of rupees, with patients being asked to return after two weeks.
Read more: Study Reveals COVID-19 Vaccines May Help Strengthen Cancer Treatment
Dr. Zulfiqar Soomro, In-Charge of the NIH Anti-Allergy Center, said efforts are underway to stabilize the situation. He explained that vaccine production takes time, as it undergoes 10 to 15 days of experimental stages to ensure safety and prevent any adverse reactions.
Dr. Soomro added that phenol, a key ingredient for the vaccine, became available last week but is still in the testing stage before full production can resume.
Comments are closed, but trackbacks and pingbacks are open.